COVID-19: Implications for bipolar disorder clinical care and research
- PMID: 33403113
- PMCID: PMC7739076
- DOI: 10.1177/2050312120981178
COVID-19: Implications for bipolar disorder clinical care and research
Abstract
The COVID-19 pandemic has posed significant challenges to health care globally, and individuals with bipolar disorder are likely disproportionally affected. Based on review of literature and collective clinical experience, we discuss that without special intervention, individuals with bipolar disorder will experience poorer physical and mental health outcomes due to interplay of patient, provider and societal factors. Some risk factors associated with bipolar disorder, including irregular social rhythms, risk-taking behaviours, substantial medical comorbidities, and prevalent substance use, may be compounded by lockdowns, social isolation and decrease in preventive and maintenance care. We further discuss implications for clinical research of bipolar disorders during the pandemic. Finally, we propose mitigation strategies on working with individuals with bipolar disorder in a clinical and research context, focusing on digital medicine strategies to improve quality of and accessibility to service.
Keywords: Bipolar disorder; coronavirus infections; pandemics.
© The Author(s) 2020.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.I.H. reports grants from Stanley Medical Research Institute during the conduct of the study, personal fees from COMPASS Pathways Limited, grants from PSI Foundation and grants from Brain and Behavior Research Foundation outside the submitted work, and was previously appointed as Member, Board of Trustees of Pakistan Institute of Living and Learning. Z.J.D. reports research and equipment in-kind support in the last 5 years for an investigator-initiated study through Brainsway Inc and Magventure Inc. His work is supported by the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), Brain Canada and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. BHM reports research financial support from Brain Canada, CAMH Foundation, CIHR, and US National Institutes of Health; nonfinancial support from Pfizer (medication for an NIH-funded trial), Eli Lilly (medication and matching placebo for an NIH-funded trial), Capital Solution Design LLC (software for a trial funded by the CAMH Foundation), and HAPPYneuron (software for a trial funded by Brain Canada). He directly owns shares of General Electric (less than $5000).
References
-
- Johns Hopkins University. Coronavirus COVID-19 global cases by the centre for systems science and engineering, https://coronavirus.jhu.edu/map.html (accessed 1 April 2020).
-
- Centres for Disease Control Prevention. Cases in U.S, https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html (accessed 1 April 12020).
-
- Cheng SK, Wong CW, Tsang J, et al. Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS). Psychol Med 2004; 34(7): 1187–1195. - PubMed
-
- Lee AM, Wong JG, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry 2007; 52(4): 233–240. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
